Coagulation Dysfunction Criteria in Critically Ill Children: The PODIUM Consensus Conference.


Journal

Pediatrics
ISSN: 1098-4275
Titre abrégé: Pediatrics
Pays: United States
ID NLM: 0376422

Informations de publication

Date de publication:
01 01 2022
Historique:
accepted: 24 09 2021
entrez: 31 12 2021
pubmed: 1 1 2022
medline: 23 2 2022
Statut: ppublish

Résumé

Previous criteria for coagulation dysfunction in critically ill children were based mainly on expert opinion. To evaluate current evidence regarding coagulation tests associated with adverse outcomes in children to inform criteria for coagulation dysfunction during critical illness. Electronic searches of PubMed and Embase were conducted from January 1992 to January 2020 by using a combination of medical subject heading terms and text words to define concepts of coagulation dysfunction, pediatric critical illness, and outcomes of interest. Studies were included if critically ill children with coagulation dysfunction were evaluated, if performance characteristics of assessment and/or scoring tools to screen for coagulation dysfunction were evaluated, and if outcomes related to mortality or functional status, organ-specific outcomes, or other patient-centered outcomes were assessed. Data were abstracted from each eligible study into a standard data extraction form, along with risk of bias assessment, by a task force member. The systematic review supports the presence of at least 2 of the following criteria reflecting coagulation dysfunction in the absence of liver dysfunction: platelet count <100 000 cells per μL, international normalized ratio >1.5, fibrinogen level <150 mg/dL, and D-dimer value above 10 times the upper limit of normal, or above the assay's upper limit of detection if this limit is below 10 times the upper limit of normal. The proposed criteria for coagulation dysfunction are limited by the available evidence and will require future validation. Validation of the proposed criteria and identified scientific priorities will enhance our understanding of coagulation dysfunction in critically ill children.

Identifiants

pubmed: 34970670
pii: 184276
doi: 10.1542/peds.2021-052888L
doi:

Substances chimiques

Fibrin Fibrinogen Degradation Products 0
fibrin fragment D 0
Fibrinogen 9001-32-5

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

S79-S83

Investigateurs

Melania M Bembea (MM)
Michael Agus (M)
Ayse Akcan-Arikan (A)
Peta Alexander (P)
Rajit Basu (R)
Tellen D Bennett (TD)
Desmond Bohn (D)
Ann-Marie Brown (AM)
Joseph A Carcillo (JA)
Paul Checchia (P)
Jill Cholette (J)
Ira M Cheifetz (IM)
Timothy Cornell (T)
Allan Doctor (A)
Michelle Eckerle (M)
Simon Erickson (S)
Reid W D Farris (RWD)
Julie C Fitzgerald (JC)
Dana Y Fuhrman (DY)
John S Giuliano Jr (JS)
Kristin Guilliams (K)
Michael Gaies (M)
Stephen M Gorga (SM)
Mark Hall (M)
Mary Hartman (M)
Amanda B Hassinger (AB)
Sharon Y Irving (SY)
Howard Jeffries (H)
Philippe Jouvet (P)
Sujatha Kannan (S)
Robinder G Khemani (RG)
Niranjan Kissoon (N)
Jacques Lacroix (J)
Peter Laussen (P)
Francis Leclerc (F)
Jan Hau Lee (JH)
Stephane Leteurtre (S)
Katie Lobner (K)
Patrick J McKiernan (PJ)
Kusum Menon (K)
Jennifer A Muszynski (JA)
Folafoluwa Odetola (F)
Nazima Pathan (N)
Richard W Pierce (RW)
Jose Pineda (J)
Jose M Prince (JM)
Karen A Robinson (KA)
Courtney M Rowan (CM)
Lindsay M Ryerson (LM)
L Nelson Sanchez-Pinto (LN)
Luregn J Schlapbach (LJ)
David T Selewski (DT)
Lara S Shekerdemian (LS)
Dennis Simon (D)
Lincoln S Smith (LS)
James E Squires (JE)
Robert H Squires (RH)
Scott M Sutherland (SM)
Yves Ouellette (Y)
Michael C Spaeder (MC)
Vijay Srinivasan (V)
Marie E Steiner (ME)
Robert C Tasker (RC)
Ravi Thiagarajan (R)
Neal Thomas (N)
Pierre Tissieres (P)
Chani Traube (C)
Marisa Tucci (M)
Katri V Typpo (KV)
Mark S Wainwright (MS)
Shan L Ward (SL)
R Scott Watson (RS)
Scott Weiss (S)
Jane Whitney (J)
Doug Willson (D)
James L Wynn (JL)
Nadir Yehya (N)
Jerry J Zimmerman (JJ)

Informations de copyright

Copyright © 2021 by the American Academy of Pediatrics.

Déclaration de conflit d'intérêts

FINANCIAL DISCLOSURE: The authors have indicated they have no financial relationships relevant to this article to disclose.

Auteurs

E Vincent S Faustino (EVS)

Section of Pediatric Critical Care Medicine, Department of Pediatrics, School of Medicine, Yale University, New Haven, Connecticut.

Oliver Karam (O)

Division of Pediatric Critical Care Medicine, Children's Hospital of Richmond at Virginia Commonwealth University, Richmond, Virginia.

Robert I Parker (RI)

Hematology/Oncology, Department of Pediatrics (Emeritus), Renaissance School of Medicine, Stony Brook University, Stony Brook, New York.

Sheila J Hanson (SJ)

Critical Care Section, Department of Pediatrics, Medical College of Wisconsin and Children's Wisconsin, Milwaukee, Wisconsin.

Leonardo R Brandão (LR)

Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.
Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.

Paul Monagle (P)

Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia.
Department of Clinical Haematology, The Royal Children's Hospital Melbourne, Parkville, Victoria, Australia.
Murdoch Children's Research Institute, Parkville, Victoria, Australia.
Kids Cancer Centre, Sydney Children's Hospital, Randwick, New South Wales, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH